KR102119421B1 - Composition for Anti-Allergy Using an Extract of Catalpa ovata - Google Patents

Abstract

The present invention discloses a composition for anti-allergic using a paulownia extract showing inhibitory activity of degranulation when treated with mast cell line RBL-2H3 (rat basophilic leukemia) activated with IgE and antigen (DNP-BSA).

Description

Composition for anti-allergy using a paulownia extract {Composition for Anti-Allergy Using an Extract of Catalpa ovata}

The present invention relates to a composition for anti-allergy using a extract of Catalpa ovata .

Allergy is a compound word created by combining'allos', meaning'changing' in Greek, and'ergo', meaning'action'. As in etymology, allergen, an allergic substance that does not respond to an average person, is an abnormal innate or acquired immune function that causes hypersensitivity reactions such as hives, itchiness, runny nose, and cough in certain people. Typical allergens include pollen, drugs, vegetable fibers, germs, fungi, house dust mites, food (egg albumin, milk protein, peanuts), dyes, chemicals, and allergies such as recent increases in indoor life, new material chemicals, etc. These allergic diseases are increasing worldwide due to increased substances, environmental pollution, reduced immune function due to stress, and changes in diet.

Allergic reactions are classified into five types: type I anaphylaxis type, type II cell lysis type, type III immunocomplex type, type IV cell mediation type, and type V stimulatory hypersensitivity type, most of which belong to type I. The allergic reaction is used in the same sense as type I (Roitt I, Brostoff J, Male D. Immunology 6th eds. USA. Mosby. 2001:323-383).

Representative allergic diseases include atopic dermatitis, bronchial asthma, allergic rhinitis, allergic keratitis, and skin hives, and mast cells are known as important effector cells for these allergic diseases (Wills-Karp M., et al., Science, 282:2258-61, 1998; Grunig G., et al., Science, 282:2261-2263, 1998). Mast cells are cells that are widely distributed in organs of the whole body, such as the skin, respiratory system, lymphatic vessels, mucous membranes of the gastrointestinal tract, blood vessels, and brain (Ishizaka t., et al. J. Immunol. 119:1589, 1997).

Allergic reactions are induced through activation of the intracellular signaling pathway when allergens bind to IgE bound to the IgE high affinity receptor (FcεRI) on the mast cell surface. Specifically, when the allergen invades a living body, T-helper cells and B cells are sequentially activated to generate IgE. Allergen support invading the living body is recognized by antigen-presenting cells, and the antigen-presenting cells differentiate Th0 (T helper cell type 0) into Th2 cells through allergen presentation. These differentiated Th2 cells secrete cytokines such as IL-4, IL-5 and IL-13, which promote acidic leukocyte development in the bone marrow, as well as inducing acidic leukocytes to inflamed tissues, as well as B cells Act on to induce the production of IgE and IgG1.

The thus produced IgE binds to the high-affinity IgE receptor (FcRIα) of the mast cell membrane, and when allergens such as ticks and pollen are bound to form a crosslink, the receptor (FcRIα) aggregates. Mast cells are activated by cross-linking and aggregation of the receptor (FcRIα), thereby increasing the concentration of calcium ions (Ca ⁺⁺ ) in the cytoplasm. The increase in the concentration of calcium ion acts on various types of intracellular regulatory factors such as cholesterol in the cell membrane or the cytoskeletal system to move granules to the cell membrane, and at the same time, through the fear of granules, fusion of granules and fusion of granules and cell membranes, degranulation Causes When degranulation, preformed mediators pre-stored in mast cells, such as histamine, are released, and at the same time, newly synthesized prostaglandin and leukotriene are secreted together. NCF acts as a chemotactic factor of inflammatory cells such as eosinophils and neutrophils in addition to histamine, serotonin and leukotriene, which have actions such as vasodilation, hyperpermeability, and contraction or secretion of bronchial smooth muscle. , ECF, PAF, etc., causing allergic reactions (Ennis M, et al., Br J Pharmacol 70:329-334, 1980; Metcalfe DD, et al., Crit Rev Immunol 3:23-74, 1981; Miyajima I, et al., J Clin Invest 99:901-914, 1997; Church MK, et al., J Allergy Clin Immunol 99:155-160, 1997; Jones DA, et al., J Biol Chem 268:9049- 9054, 1993).

Cyclooxygenase (COX) and lipoxygenase (LO) are known to catalyze a part of the process of producing prostaglandins and leukotrienes, which are allergens from arachidonic acid (Sekiya K) , et al., Biochem Biophys Acta 713: 68-72, 1982)

Therefore, substances that inhibit mast cell activation, inhibit histamine release, or inhibit the synthesis of prostaglandins and leukotriene may be effective treatments for allergies.

Antihistamines (alkylamines, desloratadine, etc.), mast cell stabilizers (such as cromoglycate), leukotriene blockers (montelukast, etc.), and anti-IgE antibodies (Omalizumab) are currently used as anti-allergic drugs. However, most of these drugs have temporary effects and often have severe side effects. Therefore, it can be said that there is still a need for the development of new substances with low side effects and lasting effects while having an allergic disease prevention and improvement effect. In particular, natural products have relatively low toxicity.

The present invention discloses the anti-allergic activity of the paulownia extract.

An object of the present invention is to provide a composition for anti-allergic using a paulownia extract.

Other or specific objects of the present invention will be presented below.

The present invention, as can be seen in the Examples and Experimental Examples below, beta-hexosamina when the paulownia extract is treated with the mast cell line RBL-2H3 (rat basophilic leukemia) activated with IgE and antigen (DNP-BSA) It was completed by confirming that it inhibits the production of β-hexosaminidase. The mast cell line RBL-2H3 has an IgE antibody receptor (FcεRI) on its surface, and when activated with IgE and an antigen, degranulation is induced and is known to secrete a mediator of an allergic reaction such as histamine. Sosaminidase is known as an indicator of degranulation (Planta Med. 64:577-578, 1998).

Considering the above, the present invention can be grasped as an anti-allergic composition or an antihistamine composition comprising the paulownia extract as an active ingredient.

In the present specification, the term “palm tree extract” refers to the stem, leaf, fruit, flower, root, and mixture thereof of the paulownia tree to be extracted, water, lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, butanol, etc.), methylene chloride , Ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), 1,3-butylene glycol, propylene glycol, or mixed solvents thereof The extract obtained by leaching using means an extract obtained by using a supercritical extraction solvent such as carbon dioxide or pentane or a fraction obtained by fractionating the extract, and the extraction method is cold immersion in consideration of the polarity, extraction degree and storage degree of the active substance. , Reflux, warming, ultrasonic radiation, supercritical extraction, and other methods can be applied. In the case of fractionated extracts, the fractions obtained by suspending the extracts in a specific solvent and mixing and policing with a solvent having a different polarity, adsorb the crude extract on a column filled with silica gel, etc., and then add a hydrophobic solvent, a hydrophilic solvent or a mixed solvent thereof. It means that it contains the fraction obtained as a mobile phase. In addition, the meaning of the extract includes a concentrated liquid extract or a solid extract in which the extraction solvent is removed by a method such as freeze drying, vacuum drying, hot air drying and spray drying. Preferably, it is an extract obtained using water, ethanol or a mixed solvent thereof as an extraction solvent, and more preferably an extract obtained using a mixed solvent of water and ethanol as an extraction solvent.

In addition, in the present specification, "active ingredient" refers to a component that can exhibit a desired activity alone or itself can exhibit activity with an inactive carrier.

Also, as used herein, "anti-allergic" is meant to include the improvement (alleviation of symptoms), treatment, and prevention (suppression or delay of onset) of allergic diseases as defined below.

In addition, in the present specification, "allergic disease" refers to pathological symptoms caused by allergic reaction mediated by activation of mast cells, such as degranulation of mast cells, and such allergic diseases include atopic dermatitis and asthma. , Allergic rhinitis, allergic conjunctivitis, allergic dermatitis, allergic contact dermatitis, allergic contact dermatitis, and the like.

In the composition for anti-allergy of the present invention, as long as it can exhibit anti-allergic activity, the active ingredient may be included in any amount (effective amount) according to use, formulation, blending purpose, etc., and the typical effective amount is based on the total weight of the composition. Will be determined within the range of 0.001% to 20.0% by weight. Herein, the "effective amount" means that the intended target functional and pharmacological effect, such as anti-allergic effect, is administered when the composition of the present invention is administered to a mammal, preferably a human, who is the subject of application, according to recommendations of a medical professional, Refers to the amount of active ingredient contained in the composition of the present invention. Such an effective amount can be determined empirically within the ordinary skill in the art.

Subjects to which the composition of the present invention can be applied (prescribed) are mammals and humans, particularly human beings.

The composition for anti-allergic of the present invention is to be taken through addition of similar activity such as anti-inflammatory activity, skin protection activity (suppressing skin damage due to ultraviolet rays, skin moisturizing, etc.) or for enhancing or strengthening the anti-allergic effect in addition to the active ingredient. In order to enhance the convenience of ingestion, any compound or natural extract already known in the art for safety and having known activity may be further included.

These compounds or extracts include compounds or extracts, medicines, etc. that are listed in the Pharmacopoeia of each country ("Korea Republic of Korea Pharmacopoeia"), and health functional food exhibitions of each country ("Korea Food and Drug Administration's "Health Functional Food Standards and Standards"). Laws governing the manufacture and sale of compounds or extracts and health functional foods that have been granted an item in accordance with the laws of each country governing the manufacture and sale of foods (the "Pharmaceutical Law" in Korea) ("Act on Health Functional Foods in Korea") ”) includes compounds or extracts whose functionality is recognized.

Enterococcus faecalis heat-treated dry powders, which have been individually recognized as'reducing hypersensitivity immune responses' in accordance with the Korean Act on Health Functional Foods, complexes such as guava leaf extracts, sage extracts, leaflet extracts, and picopreto powders Complex, PLAG (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol), etc., L. sakei Probio 65, which has been individually recognized for its functional improvement through hypersensitivity to skin, maintains containing gamma-linolenic acid, is a lactic acid bacteria derived from fruits and vegetables L.plantarum CJLP133, Probiotic ATP, etc., such as MSM (dimethylsulfonylmethane) with'arthritis improvement' function in Korea Health Functional Food Fair, N-acetylglucosamine with'arthritis improvement' function and'skin moisturizing' function, etc. It will correspond to the extract.

These compounds or natural extracts may be included in the antiallergic composition of the present invention together with one or more of its active ingredients.

The antiallergic composition of the present invention can be identified as a food composition in a specific embodiment.

The food composition of the present invention can be produced in any form, for example, beverages such as tea, juice, carbonated beverages, ionic beverages, processed oils such as milk, yogurt, gums, rice cakes, Chinese medicine, bread, It can be made of foods such as confectionery, noodles, tablets, capsules, pills, granules, liquids, powders, flakes, pastes, syrups, gels, jelly, bars, etc.

In addition, the food composition of the present invention can be classified into any product as long as it complies with the enforcement regulations at the time of manufacturing and distribution in terms of legal and functional classification. For example, it is a health functional food pursuant to the Korean Act on Health Functional Food, or a confectionary, soybean, tea, or beverage according to each food type in the Food Fair of the Korean Food Sanitation Act (「Food Standards and Standards」) , Special purpose foods, and the like.

The food composition of the present invention may include a food additive in addition to the active ingredient. Food additives can be generally understood as substances added to foods, mixed or infiltrated in the manufacture, processing, or preservation of foods, and their safety must be ensured because they are consumed daily and for a long time with foods. Food additives in accordance with national laws governing the manufacture and distribution of food ("Food Sanitation Act" in Korea) are limited in terms of ingredients or functions in terms of food additives with guaranteed safety. In the Korean Food Additives Fair (the Ministry of Food and Drug Safety's 「Food Additive Standards and Standards」), food additives are divided into chemical synthetic products, natural additives, and mixed preparations in terms of ingredients, and these food additives are sweeteners and flavors in terms of functionality. It is divided into agents, preservatives, emulsifiers, acidulants and thickeners.

Sweeteners are used to impart a moderate sweetness to food, and natural or synthetic ones can be used. Preferably, a natural sweetener is used, and examples of the natural sweetener include sugar sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose, and maltose.

Flavoring agents can be used to enhance taste or aroma, and both natural and synthetic ones can be used. Preferably it is a case of using a natural thing. In addition to flavor, when using natural ones, the purpose of enhancing nutrition can also be combined. The natural flavoring agent may be obtained from apples, lemons, tangerines, grapes, strawberries, peaches, etc., or may be obtained from green tea leaves, perilla, large leaves, cinnamon, chrysanthemum leaves, jasmine, and the like. In addition, those obtained from ginseng (red ginseng), bamboo shoots, aloe vera, and ginkgo can be used. Natural flavors may be liquid concentrates or solid extracts. In some cases, synthetic flavoring agents may be used. As the synthetic flavoring agent, esters, alcohols, aldehydes, terpenes, and the like may be used.

As a preservative, calcium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate, EDTA (ethylenediaminetetraacetic acid), etc. can be used, and as an emulsifier, acacia gum, carboxymethylcellulose, xanthan gum, pectin Etc. can be used, and as acidulant, arithmetic, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, phosphoric acid and the like can be used. The acidulant may be added so that the food composition has an appropriate acidity for the purpose of suppressing the growth of microorganisms in addition to the purpose of enhancing taste.

As a thickener, a suspending agent, a sedimentation agent, a gel-forming agent, a swelling agent, etc. can be used.

The food composition of the present invention may include physiologically active substances or minerals known in the art for the purpose of supplementing and reinforcing functional and nutritional properties in addition to the food additives as described above, and guaranteed stability as food additives.

Examples of such bioactive substances include catechins contained in green tea, vitamins such as vitamin B1, vitamin C, vitamin E, and vitamin B12, tocopherol, dibenzoyl thiamine, and the like, and calcium preparations such as calcium citrate and magnesium stearate as minerals. Magnesium preparations such as iron, iron preparations such as iron citrate, chromium chloride, potassium iodine, selenium, germanium, vanadium, zinc, and the like.

The food composition of the present invention may include the food additives as described above in an appropriate amount to achieve the purpose of addition according to the product type.

With regard to other food additives that may be included in the food composition of the present invention, it is possible to refer to national foods or food additives.

The composition of the present invention may be identified as a pharmaceutical composition in other specific embodiments.

The pharmaceutical composition of the present invention may be prepared in an oral dosage form or a parenteral dosage form according to the route of administration by a conventional method known in the art, including a pharmaceutically acceptable carrier in addition to the active ingredient. Here, the route of administration may be any suitable route including a local route, an oral route, an intravenous route, an intramuscular route, and direct absorption through mucosal tissue, and two or more routes may be used in combination. An example of a combination of two or more routes is when the drugs of two or more formulations according to the route of administration are combined, for example, when one drug is administered by intravenous route first and the other drug is administered by topical route secondarily.

Pharmaceutically acceptable carriers are well known in the art depending on the route of administration or formulation, and specifically refer to the pharmacopeia of each country, including "Korea Pharmacopoeia".

When the pharmaceutical composition of the present invention is prepared in an oral dosage form, powders, granules, tablets, pills, dragees, capsules, liquids, gels, syrups, suspensions, wafers according to methods known in the art with suitable carriers And the like. At this time, examples of suitable carriers include sugars such as lactose, glucose, sucrose, dextrose, sorbitol, mannitol, xylitol, starches such as corn starch, potato starch, wheat starch, cellulose, methylcellulose, ethylcellulose, sodium carboxymethylcellulose, Celluloses such as hydroxypropyl methylcellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate, mineral oil, malt, gelatin, talc, polyol, vegetable oil, ethanol, green Serol, etc. are mentioned. In the case of formulation, if necessary, suitable binders, lubricants, disintegrants, colorants, diluents, etc. may be included. Suitable binders include starch, magnesium aluminum silicate, starch ferist, gelatin, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, glucose, corn sweetener, sodium alginate, polyethylene glycol, wax, etc., and lubricants include oleic acid Sodium, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, silica, talcum, stearic acid, magnesium salts and calcium salts thereof, polydetylene glycol, and the like, and starch and methyl cellulose as disintegrants , Agar, bentonite, xanthan gum, starch, alginic acid or its sodium salt. Moreover, as a diluent, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycine, etc. are mentioned.

When the pharmaceutical composition of the present invention is prepared in a parenteral dosage form, it may be formulated in the form of injections, transdermal administrations, nasal inhalants and suppositories according to methods known in the art with suitable carriers. When formulated as an injectable agent, an aqueous isotonic solution or suspension may be used as a suitable carrier. Specifically, an isotonic solution such as PBS (phosphate buffered saline) containing triethanol amine, sterile water for injection, or 5% dextrose may be used. . When formulated as a transdermal dosage form, it can be formulated in the form of ointments, creams, lotions, gels, external solutions, pasta agents, linen agents, aerosols, and the like. For nasal inhalants, dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, etc. can be formulated in the form of an aerosol spray using a suitable propellant. witepsol), tween 61, polyethylene glycols, cacao butter, laurin, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearate, sorbitan fatty acid esters, and the like.

Regarding the specific formulation of the pharmaceutical composition, it is known in the art, and for example, see Remington's Pharmaceutical Sciences (19th ed., 1995) and the like. The above documents are regarded as part of this specification.

Preferred dosages of the pharmaceutical compositions of the present invention range from 0.001 mg/kg to 10 g/kg per day, preferably 0.001 mg/kg to 1 g per day, depending on the patient's condition, weight, sex, age, patient severity, and route of administration. /kg range. Administration can be done once a day or divided into several times. Such doses should not be construed as limiting the scope of the invention in any aspect.

In another specific aspect, the composition of the present invention can be identified as a cosmetic composition. When the composition of the present invention is identified as a cosmetic composition, its use may be understood as allergic skin trouble, skin irritation suppression use.

Even when the composition of the present invention is identified as a cosmetic composition, the cosmetic composition can be classified into any product in accordance with its use, and in particular, functional cosmetics having non-functionality such as skin trouble improvement, atopic dermatitis improvement, etc. It may be a general cosmetic. As for the product form, any product form can be taken, specifically, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, waxes It can take the form of products such as foundations and sprays. In a specific product form, it may be flexible lotion, nutrition lotion, nutrition cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder formulation.

The cosmetic composition of the present invention may include, in addition to its active ingredients, ingredients commonly used in cosmetic compositions, such as stabilizers, solubilizers, surfactants, vitamins, pigments and conventional auxiliary agents such as pigments and carriers.

When the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, trakant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide, etc. may be used as a carrier component. Can be.

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in the case of a spray, additionally chlorofluorohydrocarbon, propane /Propellant such as butane or dimethyl ether.

When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as a carrier component, specifically water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, fatty acid ester of sorbitan, and the like can be used.

When the formulation of the present invention is a suspension, liquid diluents such as water, ethanol or propylene glycol as carrier components, ethoxylated isostearyl alcohol, suspensions such as polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, microcrystals Sex cellulose, aluminum metahydroxide, bentonite, agar and the like can be used.

When the formulation of the present invention is a surfactant-containing cleansing, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivatives, methyltaurate, sarcosinate, fatty acid amide as a carrier component Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.

The cosmetic composition of the present invention can be prepared according to a method for manufacturing a cosmetic composition that is conventionally performed in the art, except that the active ingredient exhibiting anti-allergic activity is included.

As described above, according to the present invention, it is possible to provide a composition for anti-allergy using the extract of paulownia.

The composition for anti-allergy of the present invention can be commercialized as food, cosmetics, and drugs for the purpose of improving allergic diseases.

1 is a result showing the degranulation inhibitory activity in the mast cell line RBL-2H3 (rat basophilic leukemia) activated with IgE and antigen (DNP-BSA) of the paulownia extract.

Hereinafter, the present invention will be described with reference to Examples and Experimental Examples. However, the scope of the present invention is not limited to these examples and experimental examples.

< Example > Paulownia Preparation of extract

1 L of 70% ethanol was added to 100 g of the dried mixture of leaf and stem mixture of Catalpa ovata , followed by immersion extraction at room temperature for 24 hours, followed by filtration with filter paper. The obtained 70% ethanol filtrate was concentrated under reduced pressure, and then freeze-dried to obtain a paulownia extract.

< Experimental Example 2> Anti-allergic Activity experiment-β-hexosaminidase assay

The rat basophilic leukemia cell line, RBL-2H3 cell line, was 15% FBS, MEM medium containing 100 unit/ml penicillin and streptomycin, and 2×10 ⁵ /well in a 24 well plate at 37°C and 5% CO ₂ conditions. After dispensing, the cells were cultured for 24 hours.

After removing the supernatant, MEM medium containing 25 ng/ml anti-DNP IgE was added and cultured for 4 hours. After incubation, washed twice with PIPES buffer (25 mM PIPES, 119 mM NaCl, 5 mM KCl, 1 mM CaCl ₂ , 0.4 mM MgCl ₂ , 40 mM NaOH, 5.6 mM glucose, 0.1% BSA) and incubated for 10 minutes. After pre-incubation, the sample of the example was treated for 20 minutes by concentration and then reacted for 20 minutes with DNP-BSA. After standing for 10 minutes on ice to terminate the reaction, the supernatant was placed in a 96 well plate, 1 mM P-nitrophenyl-acetyl-β-D-glucosaminid was added, and the mixture was reacted at 37°C for 1 hour. After adding a stop solution (0.1M NaHCO ₃ , O.1M Na ₂ CO ₃ ) to terminate the reaction, absorbance was measured by an ELISA reader at a wavelength of 405 nm. As a positive control, ketotifen (100 μg/ml) was used.

The results of the two repeated experiments are shown in [FIG. 1], and it can be seen that the sample of the Example suppresses degranulation in a concentration-dependent manner, and the IC ₅₀ is 94.24 μg/mL. In the positive control group, ketotifen, IC ₅₀ showed 34.76 μg/mL. The ketotifen used as a positive control is an antihistamine, a drug used in allergic skin diseases such as allergic rhinitis, atopy, and allergic asthma.

Claims (6)

Contains paulownia extract as an active ingredient,
The extract is characterized in that the extract is obtained by using a mixture of leaves and stems as an extraction target, and an extraction solvent as a mixed solvent of water and ethanol.
Anti-allergic composition.
According to claim 1,
The mixed solvent is anti-allergic composition, characterized in that 70% ethanol.
delete The method according to claim 1 or 2,
The composition is an anti-allergic composition, characterized in that the pharmaceutical composition.
Contains paulownia extract as an active ingredient,
The extract is characterized in that the extract is obtained by using a mixture of leaves and stems as an extraction target, and an extraction solvent as a mixed solvent of water and ethanol.
Food composition for suppressing allergic reactions.
Contains paulownia extract as an active ingredient,
The extract is characterized in that the extract is obtained by using a mixture of leaves and stems as an extraction target, and an extraction solvent as a mixed solvent of water and ethanol.
A cosmetic composition for suppressing allergic skin troubles.

Images